Our view on alternative testing for product safety in Manufacturing Chemist

To replace a test animal, which is clearly a complex system with blood and organs, you need a more holistic approach to model the entire allergic response within the body. Our CEO Anki Malmborg Hager explains the benefits of using alternative testing methods to prove product safety in this week’s Manufacturing Chemist. Read the article […]

To replace a test animal, which is clearly a complex system with blood and organs, you need a more holistic approach to model the entire allergic response within the body. Our CEO Anki Malmborg Hager explains the benefits of using alternative testing methods to prove product safety in this week’s Manufacturing Chemist.

Read the article here

Skin Sensitization Testing—What’s Next?

Int. J. Mol. Sci. 2019, 20(3), 666; https://doi.org/10.3390/ijms20030666   Gunilla Grundström and Carl A.K. Borrebaeck Abstract There is an increasing demand for alternative in vitro methods to replace animal testing, and, to succeed, new methods are required to be at least as accurate as existing in vivo tests. However, skin sensitization is a complex process […]

Int. J. Mol. Sci. 2019, 20(3), 666; https://doi.org/10.3390/ijms20030666  

Gunilla Grundström and Carl A.K. Borrebaeck

Abstract

There is an increasing demand for alternative in vitro methods to replace animal testing, and, to succeed, new methods are required to be at least as accurate as existing in vivo tests. However, skin sensitization is a complex process requiring coordinated and tightly regulated interactions between a variety of cells and molecules. Consequently, there is considerable difficulty in reproducing this level of biological complexity in vitro, and as a result the development of non-animal methods has posed a major challenge. However, with the use of a relevant biological system, the high information content of whole genome expression, and comprehensive bioinformatics, assays for most complex biological processes can be achieved. We propose that the Genomic Allergen Rapid Detection (GARD™) assay, developed to create a holistic data-driven in vitro model with high informational content, could be such an example. Based on the genomic expression of a mature human dendritic cell line and state-of-the-art machine learning techniques, GARD™ can today accurately predict skin sensitizers and correctly categorize skin sensitizing potency. Consequently, by utilizing advanced processing tools in combination with high information genomic or proteomic data, we can take the next step toward alternative methods with the same predictive accuracy as today’s in vivo methods—and beyond.

Keywords

genomics; machine learning; skin sensitization; adverse outcome pathways; next generation in vitro tests

Article online

Merry Christmas and a Happy New Year!

SenzaGens attended BioFIT in Lille, France

On December 4-5, SenzaGen was attending BioFIT in Lille, France. BioFIT is a business development meeting with focus on early stage innovations including pre-clinical stage assets. We met with CROs and life science companies from all over Europe in search of screening tools at pre-clinical stage. Read more about Biofit here: https://www.biofit-event.com

On December 4-5, SenzaGen was attending BioFIT in Lille, France. BioFIT is a business development meeting with focus on early stage innovations including pre-clinical stage assets. We met with CROs and life science companies from all over Europe in search of screening tools at pre-clinical stage. Read more about Biofit here: https://www.biofit-event.com

SenzaGen attends Society of Toxicology (STC) of Canada’s 50th Annual Symposium

SenzaGen is attending the Society of Toxicology (STC) of Canada’s 50th Annual Symposium, on December 10-12 in Toronto, Canada. Joshua Schmidt, Business Development Director Americas at SenzaGen, will participate at the symposium and present the poster:  GARD – Assessing Skin and Respiratory Sensitizers in vitro using a genomics-based platform. STC is a non-profit association whose objectives […]

SenzaGen is attending the Society of Toxicology (STC) of Canada’s 50th Annual Symposium, on December 10-12 in Toronto, Canada. Joshua Schmidt, Business Development Director Americas at SenzaGen, will participate at the symposium and present the poster:  GARD – Assessing Skin and Respiratory Sensitizers in vitro using a genomics-based platform.

STC is a non-profit association whose objectives are to promote the acquisition, facilitate the dissemination, and encourage the utilization of knowledge in the science of toxicology. They support continuing education and excellence in research through its Annual Symposium, which provides a venue for members and international experts to present the latest advances in experimental and regulatory toxicology.

To book a meeting, please email Joshua Schmidt at:

joshua.schmidt (a) senzagen.com

Hope to see you there!

For more information about the symposium, please visit:

https://www.fourwav.es/view/803/info/

SenzaGen speaks at Eurofins Human Safety Seminar, November 29

Dr Andy Forreryd, scientist at SenzaGen, is one of three speakers at the Human Safety Seminar organised by Eurofins BioPharma Product Testing Munich where he will be presenting the GARD® platform for skin and respiratory sensitization. The seminar will be hosted on November 29 at the new laboratory and office building of Eurofins Munich, Robert-Koch-Straße 3a in Planegg near Munich, Germany. […]

Dr Andy Forreryd, scientist at SenzaGen, is one of three speakers at the Human Safety Seminar organised by Eurofins BioPharma Product Testing Munich where he will be presenting the GARD® platform for skin and respiratory sensitization. The seminar will be hosted on November 29 at the new laboratory and office building of Eurofins Munich, Robert-Koch-Straße 3a in Planegg near Munich, Germany.

The topics for the seminar are:

  • In vitro Methods to test for Endocrine Disrupting Properties
  • In vitro Skin sensitization – Challenges to Overcome
  • Eye Irritation ex vivo and in vitro methods – Current status
  • GARD® platform, genomic test for skin and respiratory sensitization with potency classification
  • New Developments in Genotoxicity Testing for Chemicals, Cosmetics and Pharmaceuticals – in vitro and in vivo Comet Assay

For more information and registration:

https://www.eurofins.com/human-safety-seminar

SenzaGen attends the Biocompatibility Summit in Barcelona

SenzaGen is attending the Biocompatibility Summit in Barcelona this week, on November 27-29. The summit will address updates and changes to the ISO 10993 standards and Biocompatibility for devices with a focus on Risk Mitigation, Chemical Characterisation and Practical Implementation. Come meet our colleagues and specialists Rose Marie Jenvert, Medical Device Project Manager and Joshua Schmidt, […]

SenzaGen is attending the Biocompatibility Summit in Barcelona this week, on November 27-29. The summit will address updates and changes to the ISO 10993 standards and Biocompatibility for devices with a focus on Risk Mitigation, Chemical Characterisation and Practical Implementation.

Come meet our colleagues and specialists Rose Marie Jenvert, Medical Device Project Manager and Joshua Schmidt, Business Development Director – Americas there!

To book a meeting, please email them at:

rose-marie.jenvert (a) senzagen.com
joshua.schmidt (a) senzagen.com

https://lifesciences.knect365.com/biocompatibility/

SenzaGen attends the SFT annual meeting, November 27-28

SenzaGen is attending the SFT conference (Société Française de Toxicologie) in Lille, France, on November 27-28. The conference is the French Society of Toxicology’s annual meeting and SenzaGen is present with a poster: GARD® – Genomic Allergen Rapid Detection, In vitro Safety Assessment of Skin and Respiratory Sensitizers using a Genomics Based Platform. Our French […]

SenzaGen is attending the SFT conference (Société Française de Toxicologie) in Lille, France, on November 27-28. The conference is the French Society of Toxicology’s annual meeting and SenzaGen is present with a poster: GARD® – Genomic Allergen Rapid Detection, In vitro Safety Assessment of Skin and Respiratory Sensitizers using a Genomics Based Platform. Our French distribution partner Eurosafe is also present with a booth where you can get more information about GARD® and about our collaboration with Eurosafe.

View Live: SenzaGen’s CEO at Financial Meetings Øresund

Live presentations at Financial Meetings Øresund’s event “Sverige fortsatt starkt för Life Science?” SenzaGen’s CEO Anki Malmborg Hager will share the inspiring story of SenzaGen and how SenzaGen’s platform GARD®, a group of tests for animal-free safety testing, can replace animal tests using genomics in test tubes to assess whether chemicals are allergenic or not. Watch live […]

Live presentations at Financial Meetings Øresund’s event “Sverige fortsatt starkt för Life Science?”

SenzaGen’s CEO Anki Malmborg Hager will share the inspiring story of SenzaGen and how SenzaGen’s platform GARD®, a group of tests for animal-free safety testing, can replace animal tests using genomics in test tubes to assess whether chemicals are allergenic or not.

Watch live presentation here:

http://www.financialmeetings.se/live/

SenzaGen’s CEO to speak at Financial Meetings Øresund, in Lund November 19, 2018

SenzaGen’s CEO Anki Malmborg Hager will speak at Financial Meetings Øresund, November 19, 2018. As a speakers in the event “Sverige fortsatt starkt för Life Science? Anki will share the inspiring story of SenzaGen and how SenzaGen’s platform GARD®, a group of tests for animal-free safety testing, can replace animal tests using genomics in test tubes to assess […]

SenzaGen’s CEO Anki Malmborg Hager will speak at Financial Meetings Øresund, November 19, 2018.

As a speakers in the event “Sverige fortsatt starkt för Life Science? Anki will share the inspiring story of SenzaGen and how SenzaGen’s platform GARD®, a group of tests for animal-free safety testing, can replace animal tests using genomics in test tubes to assess whether chemicals are allergenic or not.

For more information and registration,
see: http://www.financialmeetings.se/arrangemang